Observations placeholder
Imatinib Mesylate
Identifier
019124
Type of Spiritual Experience
Number of hallucinations: 7
Background
A description of the experience
Imatinib (INN), marketed as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
On Dec, 21, 2015: 2,328 people reported to have side effects when taking Imatinib mesylate. Among them, 7 people (0.30%) have Hallucination.
Time on Imatinib mesylate when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 16.67% | 83.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Dec, 21, 2015: 2,328 people reported to have side effects when taking Imatinib mesylate. Among them, 641 people (27.53%) have Death.
Time on Imatinib mesylate when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 15.91% | 22.73% | 6.82% | 20.45% | 15.91% | 18.18% | 0.00% |
Gender of people who have Death when taking Imatinib mesylate :
| Female | Male | |
| Death | 31.96% | 68.04% |
Age of people who have Death when taking Imatinib mesylate :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 2.21% | 9.56% | 12.13% | 23.16% | 16.54% | 36.40% |